<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582033</url>
  </required_header>
  <id_info>
    <org_study_id>SGNBCMA-001</org_study_id>
    <nct_id>NCT03582033</nct_id>
  </id_info>
  <brief_title>A Safety Study of SEA-BCMA in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple
      myeloma (MM) and what side effects (unwanted effects) may occur.

      The study will have two parts. In the first part, participants get SEA-BCMA by itself. This
      part of the study will find out how much SEA-BCMA should be given for treatment and how
      often. It will also find out how safe the treatment is and how well it works.

      In the second part of the study, participants will be given both SEA-BCMA and dexamethasone.
      Dexamethasone is a drug that can be used to treat multiple myeloma. The part will study
      whether SEA-BCMA and dexamethasone are safe when used together.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting one or more treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Grade 3 or higher adverse events (AEs)</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
    <description>AE grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant but not immediately life-threatening; Grade 4 - life-threatening consequences; Grade 5 - death related to AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting one or more serious adverse event (SAE)</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a treatment-related AE</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities by grade</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
    <description>Grades for laboratory abnormalities will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Through up to 28 days following first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) outcome: Cmax (maximum serum concentration)</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK outcome: AUC (area under the serum concentration-time curve)</measure>
    <time_frame>Through 84 days following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SEA-BCMA antitherapeutic antibodies (ATA)</measure>
    <time_frame>Through 30-37 days following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response per the IMWG uniform response criteria</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>International Myeloma Working Group (IMWG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The proportion of patients with stringent complete response, complete response, very good partial response, or partial response per investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response (OR) and complete response (CR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from first documentation of CR or OR to the first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from the start of study treatment to the first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>The time from the start of study treatment to the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-BCMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-BCMA + dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEA-BCMA</intervention_name>
    <description>Given by intravenous (IV) infusion</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally or by IV infusion</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of multiple myeloma (MM)

          -  Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1

          -  Must have MM that is relapsed or refractory and must not have other therapeutic
             options available known to provide clinical benefit in MM

          -  Has received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38
             antibody

          -  Life expectancy of greater than 3 months in the opinion of the investigator

          -  Patients of childbearing potential or who can father children must agree to
             consistently use 2 effective forms of birth control for at least 6 months after the
             final dose of study drug administration

          -  Adequate hematologic, renal, and hepatic function

          -  Measurable disease, as defined by at least one of the following: (1) serum M protein
             0.5 g/dL or higher, (2) urine M protein 200 mg/24 hour or higher, and (3) serum
             immunoglobulin free light chain 10 mg/dL or higher and abnormal serum immunoglobulin
             kappa lambda free light chain ratio.

        Exclusion Criteria:

          -  Prior treatment with a BCMA-directed therapy

          -  History of another malignancy within 3 years

          -  Active cerebral or meningeal disease related to the underlying malignancy

          -  Uncontrolled Grade 3 or higher infection

          -  Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of
             study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be
             completed 8 weeks before first dose of study drug.

          -  Patients who are pregnant or breastfeeding

          -  Combination therapy only:

               1. Known intolerance to corticosteroids

               2. Uncontrolled psychoses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Campbell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Michaela Liedtke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Robert Rifkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>James Hoffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center / University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Yogesh Jethava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Al-Ola Abdallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Mark Schroeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Ruben Niesvizky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center / University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Brea Lipe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Yasenchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jason Melear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Damian Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRMM</keyword>
  <keyword>Antibodies, monoclonal</keyword>
  <keyword>Antigens, BCMA</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Hematologic diseases</keyword>
  <keyword>Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

